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Previous studies have shown the b-catenin signaling path-
way to promote the development of tolerogenic dendritic
cells (DCs) that are capable of driving regulatory T cell
(Treg) differentiation. Interestingly, tolerogenic DCs have
recently been described to play a role in carcinogenesis.
However, the molecular mechanisms underlying the estab-
lishment of immune tolerance by this DC population are
poorly understood and the methods by which developing
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Figure 1 Wnt3a and Wnt5a upregulate IDO expression and activity in DCs. A. Wnt5a induces durable IDO expression by BMDCs based on
Western blot analysis at 24 and 48 hrs. Representative of 3 independent experiments. UT, untreated. XAV939, b-catenin inhibitor. B. Both Wnt3a and
Wnt5a activate the IDO promoter in COS7 cells transiently transfected with a IDOprom-luciferase reporter plasmid. Performed in triplicate.
Representative of 2 independent experiments. P value based on a one-way ANOVA. C. Wnt5a induces DC-derived IDO enzymatic activity based on
kynurenine detection by HPLC. Cumulative data from 3 separate experiments. P value based on one-way ANOVA. D. Wnt3a and Wnt5a Stimulate b-
catenin Activity in Primary TCF/Lef1-EGFP DCs in vitro. Representative of 2 independent experiments. E. Wnt3a and Wnt5a Induce b-catenin-IDO
promoter binding in Primary DCs. Performed after 24 hrs of stimulation. IFN-g induction of STAT1 binding to the IDO promoter serves as positive
control. Bottom, Western blot generated from same samples. *P < 0.05. P value based on one-way ANOVA. F. b-catenin immunofluorescence
microscopy confirms differential kinetics of Wnt3a- and Wnt5a-induced signaling in DCs. Bottom, examples of b-catenin nuclear translation in response
to Wnt3a and Wnt5a (100x). 10 fields counted in triplicate. Representative of 2 independent experiments. All data is mean ± SEM.
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cancers can co-opt this pathway to subvert immune
surveillance are unknown. Using a genetically engineered
model, we demonstrate that melanoma-derived Wnt5a
ligand is a novel regulator of indoleamine 2,3-dioxygenase-
1 (IDO) expression in local myeloid DCs and that Wnt5a
induces the durable expression and enzymatic activity of
IDO via b-catenin (Figures 1,2). Further, we show that
Wnt5a-conditioned DCs promote Treg differentiation in
an IDO-dependent manner and that melanoma secretion
of Wnt5a both suppresses the generation of anti-tumor
immunity and promotes melanoma progression in vivo
(Figure 3). By genetically silencing the PORCN acyl trans-
ferase which is necessary for Wnt ligand secretion, we
confirm the role of the soluble Wnt ligands in directing
Figure 2 Murine melanomas induce paracrine b-catenin signaling activation in tumor and TDLN DCs in vivo. A.Tumor-infiltrating DCs
(TIDCs) isolated from Tyr::CreER;BrafCA;Ptenlox/lox primary melanomas exhibit increased expression levels of b-catenin target genes, including axin2,
ccnd1, c-myc, and tcf-7, based on qrt-PCR relative to BMDCs derived from non-tumor bearing mice. Representative of 2 independent
experiments. P value based on a two-way ANOVA. B. DCs isolated from tumor-draining lymph node (TDLN) tissues harvested from melanoma-
bearing Tyr::CreER;BrafCA;Ptenlox/lox mice exhibit elevated expression levels of b-catenin target genes relative to distant LN tissues harvested from
the same mice as well as LN tissues harvested from non-tumor-bearing cre- control mice. Representative of 2 independent experiments. P value
based on a two-way ANOVA. C. b-catenin signaling activation in CD11c+ DCs derived from primary BRAFV600EPTEN-/- melanomas and TDLNs
harvested from TCF/Lef1-EGFP reporter mice. Left, flow cytometry analysis and quantitation of GFP+CD11c+ DCs. Representative of 2 independent
experiments. Right, immunofluorescence confocal microscopy of a GFP+CD11c+ DC isolated from a BRAFV600EPTEN-/- primary melanoma. D.
Confocal microscopy of a resected BRAFV600EPTEN-/- melanoma resected from a TCF/Lef1-EGFP reporter mouse demonstrates a GFP-positive
stromal infiltrate. Representative of 3 analyzed tumors. 60x. E. Left, Confocal immunofluorescence microscopy of TDLN tissue resected from TCF/
Lef1-EGFP reporter mice demonstrates evidence of GFP+ lymph node cells. Center, TDLN tissue resected from wild type (WT) BRAFV600EPTEN-/-
melanoma-bearing mice. Right, TDLN tissue from TCF/Lef1-EGFP reporter mice counterstained for CD11c expression shows evidence of GFP
+CD11c+ DCs (arrows). Representative of 3 analyzed lymph nodes. 60x.
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Figure 3 Wnt5a conditions DCs to drive regulatory T-cell differentiation. A. Schematic of in vitro Treg assay. B. Wnt5a-conditioned DCs
stimulate CD4+FoxP3+ Treg differentiation in vitro following co-incubation with total splenic CD4+ T cells at a 1:1, 5:1 or 10:1 T cell to DC ratio. CD4+FoxP3+
Tregs were quantitated by flow cytometry. Representative of 3 independent experiments. C. DCs pre-conditioned for 24 and 48 hrs stimulate CD4+FoxP3+
Treg differentiation in vitro following co-incubation with naive splenic CD4+CD62L+ T cells. DCs were pretreated Wnt3a or Wnt5a for 24 or 28 hrs then
co-incubated with splenic naïve CD4+ T cells with or without the IDO inhibitor, 1-MT. CD4+FoxP3+ Tregs were quantitated by flow cytometry. Performed in
triplicate. Data is normalized to untreated DC condition. Representative of 3 independent experiments. P values based on a two-way ANOVA.
Figure 4 Silencing PORCN expression in the B16 melanoma model enhances anti-tumor immunity and suppresses tumor progression
in vivo. A. Silencing PORCN expression by B16/F10 cells suppresses paracrine b-catenin activation in a 293T-TCF/LEF1-luciferase reporter cell line.
NTC, non-targeted control. KD, knock-down. Performed in triplicate. Representative of 3 independent experiments. P value based on two-tailed
student’s t test. B. PORCN silencing suppresses Wnt5a secretion from B16/F10 melanoma cells. Top, CM was harvested from HA-Wnt5a
transfected B16-NTC cells treated with increasing concentrations of C59 (left) and HA-sRIII or HA-Wnt5a transfected B16-PORCNKD cells (right) and
immunoprecipitated with an anti-HA antibody. Bottom, Total cell lysates from HA-Wnt5a transfected B16-NTC were treated with increasing
concentrations of C59 (left) and HA-sRIII or HA-Wnt5a transfected B16-PORCNKD cells (right) were analyzed by anti-HA Western blot. HA-sRIII, HA-
tagged soluble ectodomain of type III TGF-b receptor used as a positive control for protein secretion. Representative of two independent
experiments. C. Wnt5a detection in the CM of B16-NTC and B16-PORCNKD cells by ELISA. Cumulative data from 3 independent experiments. P
value based on two-tailed student’s t test. D. The B16-NTC and B16-PORCNKD cell lines were implanted in C57BL/6 mice and tumor growth was
monitored by orthogonal caliper measurements. 10 mice per group. Statistical significance based on Mann-Whitney U-test. *P < 0.05. E. Tumor-
infiltrating CD3+CD8+ T lymphocyte populations are increased in PORCN silenced B16/F10 tumors based on flow cytometry. Performed in
triplicate. Representative of 2 independent experiments. P value based on two-tailed student’s t test. F. Tumor-infiltrating CD8+ T lymphocytes in
PORCN silenced B16/F10 tumors exhibit diminished levels of surface PD-1 expression based on flow cytometry. Performed in triplicate.
Representative of 2 independent experiments. P value based on two-tailed student’s t test.
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DC tolerization both in vitro and in vivo while also estab-
lishing a potential pharmacologic target for manipulat-
ing this novel pathway (Figure 4). Indeed, utilizing a
small molecule inhibitor of PORCN, we are able to
reverse Wnt5a-mediated IDO upregulation by DCs both
in vitro and in vivo. These findings were expanded in
further melanoma studies where we demonstrated small
molecule PORCN inhibition to synergistically suppress
melanoma progression while also enhancing anti-
melanoma immunity in the setting of combination anti-
CTLA-4 therapy (Figure 5). Additional work in human
melanoma confirms the existence of this Wnt5a-
mediated paracrine signaling pathway in DCs and
reveals by microarray dataset analysis that human mela-
noma co-expression of Wnt5a and FoxP3 is highly sig-
nificant. These data prompted us to hypothesize that a
Wnt5a-induced gene signature in the melanoma micro-
environment may be indicative of immune tolerance.
Indeed, we have found that a Wnt5a gene signature
identified in purified sentinel lymph node-derived DCs
is associated with an inferior clinical prognosis in mela-
noma patients. This work emphasizes the importance of
DC populations in directing tumor immune surveillance
and illustrates that the molecular mechanisms involved
in DC physiology represent potential targets for phar-
macologically enhancing anti-tumor immunity.
Figure 5 C59 Inhibition of the Wnt-b-catenin signaling pathway synergistically enhances the efficacy of anti-CTLA-4 antibody
immunotherapy in the B16 melanoma model. A. Combination inhibition of Wnt-mediated signaling and anti-CTLA-4 blockade synergistically
suppresses B16 melanoma development in vivo. B16/F10 tumor-bearing mice were administered C59 alone at 5 mg/kg/day by oral gavage, anti-
CTLA-4 mAb alone at 100 μg via intra-peritoneal injection every 3 days, or the combination. Control mice (UT, untreated) received daily vehicle
control by oral gavage and isotype control antibody every 3 days. 5-6 mice per group. Representative of two independent experiments. B.
Inhibition of Wnt secretion enhances the activation of B16/F10 melanoma-infiltrating CD8+ T cells. Tumor-infiltrating 41BB+CD8+ T cells in each
treatment group were analyzed by flow cytometry. 4 mice per group. Representative of 2 independent experiments. P value based on a one-
way ANOVA. C. Inhibition of Wnt secretion augments anti-CTLA-4 mAb-induced expansion of TRP2-specific CD8+ T cells in B16/F10 melanomas
based on dextramer flow cytometry analysis. 4 mice per group. Representative of 2 independent experiments. P value based on a one-way
ANOVA.
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